Finasteride

Generic Name: Finasteride

Brand Names: Entadfi, Propecia, Proscar

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₆N_₂O_₂

CAS Number: 98319-26-7

Unique Ingredient Identifier: 57GNO57U7G

Background: Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an ...

Indication: Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with tadalafil is also used...

Associated Conditions: Androgenetic Alopecia (AGA), Benign Prostatic Hyperplasia (BPH), Idiopathic Hirsutism, Symptomatic benign prostatic hyperplasia (BPH)

Associated Therapies: -

Clinical Trials

Finasteride, Dutasteride and Insulin Action

Phase 2

Conditions: Healthy Volunteers

Interventions: Drug: Finasteride
Drug: Dutasteride

First Posted Date: 2013-08-14

Last Posted Date: 2013-08-14

Lead Sponsor: University of Birmingham

Target Recruit Count: 12

Registration Number: NCT01923090

Locations: 🇬🇧
Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

Phase 4

Conditions: Benign Prostate Hyperplasia

Interventions: Drug: Tamsulosin
Drug: Finasteride
Drug: Placebo

First Posted Date: 2012-11-29

Last Posted Date: 2014-05-14

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 545

Registration Number: NCT01736033

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju, Chungbuk, Korea, Republic of
🇰🇷
Eulji General Hospital, Seoul, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeoggi, Korea, Republic of

and more 8 locations

Finasteride for Chronic Central Serous Chorioretinopathy

Phase 2

Terminated

Conditions: Retinal Disease

Interventions: Drug: Placebo
Drug: Finasteride

First Posted Date: 2012-04-25

Last Posted Date: 2014-12-04

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 6

Registration Number: NCT01585441

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

Phase 3

Terminated

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Finasteride
Drug: Tamsulosin
Drug: Tamsulosin-matching placebo
Drug: Finasteride-matching placebo

First Posted Date: 2012-02-16

Last Posted Date: 2018-08-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1

Registration Number: NCT01534351

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Dutasteride
Drug: Finasteride
Radiation: Radiation

First Posted Date: 2011-04-27

Last Posted Date: 2024-05-24

Lead Sponsor: University of Chicago

Target Recruit Count: 74

Registration Number: NCT01342367

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Finasteride

First Posted Date: 2011-02-15

Last Posted Date: 2017-10-06

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 383

Registration Number: NCT01296672

Locations: 🇺🇸
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center, San Antonio, Texas, United States

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Finasteride

First Posted Date: 2010-12-21

Last Posted Date: 2010-12-21

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 26

Registration Number: NCT01264289

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas,, Nevada, United States

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Finasteride

First Posted Date: 2010-12-21

Last Posted Date: 2010-12-21

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 26

Registration Number: NCT01264302

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas,, Nevada, United States

Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

Phase 1

Completed

Conditions: Retinal Disease

Interventions: Drug: Finasteride

First Posted Date: 2010-10-25

Last Posted Date: 2024-01-30

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 3

Registration Number: NCT01227993

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

High Risk Prostate Cancer Prevention Study

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Drug: finasteride

First Posted Date: 2010-08-04

Last Posted Date: 2014-01-01

Lead Sponsor: University of Kansas

Target Recruit Count: 18

Registration Number: NCT01174953

Locations: 🇺🇸
Veterans Administration Medical Centenr, Kansas City, Missouri, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy